Trials / Completed
CompletedNCT00027586
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
Detailed description
OBJECTIVES: * Determine the clinical activity of imatinib mesylate (STI571) in patients with metastatic melanoma. * Determine the side effects of this drug in these patients. * Correlate molecular studies with responsiveness to this drug in these patients. OUTLINE: Patients receive oral imatinib mesylate (STI571) twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 21-78 patients will be accrued for this study within 6-15 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib mesylate (STI571) | 400 mg twice a day orally |
Timeline
- Start date
- 2001-09-01
- Primary completion
- 2005-01-01
- Completion
- 2005-01-01
- First posted
- 2003-01-27
- Last updated
- 2018-10-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00027586. Inclusion in this directory is not an endorsement.